Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.32 |
| ▸ | CPA1 | P15085 | 2/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valnoctamide SCHEMBL5053817 | 1.00 | CA1 (0.39) | CA1CA2CA7CA14DPP4 | |
| SCHEMBL20259104 | 0.85 | CA1 (0.35) | CA1CA2CA7CA14DPP4 | |
| SCHEMBL7511543 | 0.85 | CA1 (0.35) | CA1CA2CA7CA14EPHX1 | |
| SCHEMBL277889 | 0.83 | CA1 (0.43) | CA1CA2CA7CA14ALDH1A1 | |
| (2R,3S)-Sec-Butylpropylacetamide SCHEMBL24621638 | 0.83 | CA1 (0.43) | CA1CA2CA7CA14DPP4 | |
| SCHEMBL8314806 | 0.83 | CA1 (0.34) | CA1CA2CA7CA14DPP4 | |
| SCHEMBL12015470 | 0.83 | ACE (0.38) | CA1CA2CA7CA14DPP4 | |
| SCHEMBL3504203 | 0.83 | ECE1 (0.38) | CA1CA2CA7CA14DPP4 | |
| (2R,3S)-Sec-Butylpropylacetamide SCHEMBL1577854 | 0.83 | CA1 (0.43) | CA1CA2CA7CA14DPP4 | |
| (2R,3S)-Sec-Butylpropylacetamide SCHEMBL25669842 | 0.83 | CA1 (0.43) | CA1CA2CA7CA14DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687835-A1 | A BIPHASIC LIQUID PHARMACEUTICAL COMPOSITION OF AN ANTICONVULSANT DRUG AND THE PROCESS OF PREPARING THE SAME | Orbit Pharma Limited (GB) | 2026-02-11 | — | — | EP | claimed |
| EP-3518975-B1 | FORMULATION COMPRISING FENFLURAMINE AND CANNABIDIOL AND ITS USE IN THE TREATMENT OF SEIZURES | ZOGENIX INTERNATIONAL LTD (GB) | 2025-04-09 | — | — | EP | claimed |
| WO-2024201019-A1 | A BIPHASIC LIQUID PHARMACEUTICAL COMPOSITION OF AN ANTICONVULSANT DRUG AND THE PROCESS OF PREPARING THE SAME | ORBIT PHARMA LIMITED (GB) | 2024-10-03 | — | — | WO | claimed |
| US-11786487-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-10-17 | — | — | US | claimed |
| WO-2023178250-A1 | TREATMENT OF TUBEROUS SCLEROSIS WITH MIRDAMETINIB | SpringWorks Therapeutics Inc. (US) | 2023-09-21 | — | — | WO | claimed |
| US-11759440-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-09-19 | — | — | US | claimed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | claimed |
| US-20210393550-A1 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-12-23 | — | — | US | claimed |
| US-11040018-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-06-22 | — | — | US | claimed |
| US-20200246281-A1 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2020-08-06 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060004098-A1 | Compounds useful for treating neurological disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-01-05 | — | — | US | claimed |
| WO-2005009430-A1 | COMPOUNDS USEFUL FOR TREATING NEUROLOGICAL DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-02-03 | — | — | WO | claimed |
| US-20030212131-A1 | Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them | BIALER MEIR (IL) | 2003-11-13 | — | — | US | claimed |
| EP-0966429-B1 | VALNOCTAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND SEPARATION AND USES THEREOF | YISSUM RES DEV CO (IL) | 2003-06-04 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| US-6417399-B1 | ETHYLATION OF ISOLEUCINE TO 3-METHYLVALERIC ACID; HALOACYLATION TO METHYL VALEROYL CHLORIDE; CARBOXYLATION TO VALNOCTIC ACID; AMIDATION TO VALNOCTAMIDE; ANTIEPILEPTIC AGENTS; PSYCHOLOGICAL DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-07-09 | — | — | US | claimed |
| EP-0966429-A1 | VALNOCTAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND SEPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1999-12-29 | — | — | EP | claimed |
| WO-1998030536-A1 | VALNOCTAMIDE STEREOISOMERS, A METHOD FOR THEIR SYNTHESIS AND SEPARATION AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-16 | — | — | WO | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246281-A1 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | HTR2B, HTR1B, CYP4B1 | CA1 4608/4885CA2 4148/4885CA7 4785/4885 |
| US-20030212131-A1 | Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them | ADCYAP1R1, GRIN2A, PTGER1 | CA1 1049/4885CA2 1385/4885CA7 2706/4885 |
| US-20060004098-A1 | Compounds useful for treating neurological disorders | GAP43, CLN6, NLN | CA1 2293/4885CA2 2362/4885CA7 4002/4885 |
| US-11040018-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | HTR2B, HTR1B, CYP4B1 | CA1 4608/4885CA2 4148/4885CA7 4785/4885 |
| US-11759440-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | HTR2B, HTR1B, CYP4B1 | CA1 4608/4885CA2 4148/4885CA7 4785/4885 |
| US-11786487-B2 | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same | HTR2B, HTR1B, CYP4B1 | CA1 4608/4885CA2 4148/4885CA7 4785/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | CA1 2398/4885CA2 1281/4885CA7 4265/4885 |
| US-20210393550-A1 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | HTR2B, HTR1B, CYP4B1 | CA1 4608/4885CA2 4148/4885CA7 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.